EP1562978A4 - Rapid induction of alzheimer s amyloid plaque formation by sulfated glycosaminoglycans - Google Patents

Rapid induction of alzheimer s amyloid plaque formation by sulfated glycosaminoglycans

Info

Publication number
EP1562978A4
EP1562978A4 EP03778061A EP03778061A EP1562978A4 EP 1562978 A4 EP1562978 A4 EP 1562978A4 EP 03778061 A EP03778061 A EP 03778061A EP 03778061 A EP03778061 A EP 03778061A EP 1562978 A4 EP1562978 A4 EP 1562978A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
plaque formation
amyloid plaque
rapid induction
sulfated glycosaminoglycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03778061A
Other languages
German (de)
French (fr)
Other versions
EP1562978A2 (en
Inventor
Beth P Nguyen
Paula Y Choi
Virginia J Sanders
Gerardo M Castillo
Alan D Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoTech Inc
Original Assignee
ProteoTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoTech Inc filed Critical ProteoTech Inc
Publication of EP1562978A2 publication Critical patent/EP1562978A2/en
Publication of EP1562978A4 publication Critical patent/EP1562978A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP03778061A 2002-11-01 2003-10-31 Rapid induction of alzheimer s amyloid plaque formation by sulfated glycosaminoglycans Withdrawn EP1562978A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42318502P 2002-11-01 2002-11-01
US423185P 2002-11-01
PCT/US2003/034797 WO2004041779A2 (en) 2002-11-01 2003-10-31 Amyloid plaque formation by glycosaminoglycans

Publications (2)

Publication Number Publication Date
EP1562978A2 EP1562978A2 (en) 2005-08-17
EP1562978A4 true EP1562978A4 (en) 2007-10-10

Family

ID=32312619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03778061A Withdrawn EP1562978A4 (en) 2002-11-01 2003-10-31 Rapid induction of alzheimer s amyloid plaque formation by sulfated glycosaminoglycans

Country Status (5)

Country Link
EP (1) EP1562978A4 (en)
JP (1) JP4469281B2 (en)
AU (1) AU2003286845A1 (en)
CA (1) CA2504035A1 (en)
WO (1) WO2004041779A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888937B1 (en) * 2005-07-21 2012-10-26 Biomerieux Sa METHOD OF DETECTING FCPA USING FCPA AGGREGATION AGENT AND FORM AGGREGATE CAPTURING AGENT
JPWO2021200940A1 (en) * 2020-03-31 2021-10-07

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044669A1 (en) * 1996-05-23 1997-11-27 Medical Research Council Screening of agents for treatment of alzheimer's disease
WO1999045947A1 (en) * 1998-03-13 1999-09-16 University Of Washington In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044669A1 (en) * 1996-05-23 1997-11-27 Medical Research Council Screening of agents for treatment of alzheimer's disease
WO1999045947A1 (en) * 1998-03-13 1999-09-16 University Of Washington In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004041779A2 *

Also Published As

Publication number Publication date
AU2003286845A8 (en) 2004-06-07
EP1562978A2 (en) 2005-08-17
JP2006507488A (en) 2006-03-02
JP4469281B2 (en) 2010-05-26
AU2003286845A1 (en) 2004-06-07
WO2004041779A2 (en) 2004-05-21
CA2504035A1 (en) 2004-05-21
WO2004041779A3 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
HK1077288A1 (en) Method of producing titania solution
EP1745573A4 (en) Methods of manufacture of 2 -deoxy- beta-l-nucleosides
NO20033267D0 (en) Methods for increased production of pantothenate
EP1639096A4 (en) Methods of producing neurons
EP1611120A4 (en) Novel methods for the treatment of inflammatory diseases
EP1680521A4 (en) Production of titania
AU2003297630A8 (en) Photo-imageable nanocomposites
PL377943A1 (en) Method for the production of benzophenones
EP1558772A4 (en) Production of titania
EP1562978A4 (en) Rapid induction of alzheimer s amyloid plaque formation by sulfated glycosaminoglycans
GB2398029B (en) Production of disc components
PL364616A1 (en) Method of manufacture of veneered doors
IL172936A0 (en) Method for producing c1-c15 fragments of epothilones and the derivatives thereof
AU2003270233A8 (en) Production of 2 - keto - l - gulonic acd
AU2003295504A8 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
ITMI20021432A0 (en) METHOD FOR PRODUCING CEPHALOSPORINS
TW562061U (en) Structure of shaping forms
PL111906U1 (en) External fringe of window frame
TW547746U (en) Frame of lamp box
TW587485U (en) Improved mold for forming straight parts of aluminum window frame
TW576241U (en) Improved structure of goggles formable inside mold cavity
TW556510U (en) External frame of assembled box
PL111905U1 (en) Internal fringe of window frame
ZA200406777B (en) Production of abalone
TW547903U (en) Improved frame structure of electric box

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070906

17Q First examination report despatched

Effective date: 20080205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091110